Impact BioMedical Reports 57% Revenue Decline in Q2 2026, Net Loss Reduced by 95%

Impact BioMedical, Inc. has reported its financial results for the second quarter of 2026, revealing a total revenue of $3,000 for the three months ended June 30, a significant decrease of 57% compared to $7,000 in the same period of 2025. For the first half of 2026, the company generated $10,000 in revenue, which is a 43% increase from $7,000 in the first half of 2025. The revenue primarily stems from biotech retail sales related to the Celios air purification technology, a product line acquired in February 2025. Despite the increase in half-year revenue, the quarterly decline indicates challenges in maintaining sales momentum.

The company's financial performance also reflects a notable reduction in net loss, which decreased by 95% to $700,000 for the second quarter of 2026, compared to a loss of $14,352,000 in the same quarter of the previous year. For the six months ended June 30, 2026, the net loss was $2,983,000, down 81% from $15,631,000 in the first half of 2025. This improvement is attributed to a significant reduction in costs, particularly in professional fees and general administrative expenses, as well as the absence of the previous year's substantial fair value adjustments related to a note payable to a related party.

Operationally, Impact BioMedical has made strategic moves to streamline its operations, resulting in a 39% decrease in total costs and expenses for the second quarter, which amounted to $705,000 compared to $1,160,000 in the same period last year. The company has also reduced its employee compensation costs by 32% and professional fees by 78%, reflecting a focused effort to control expenditures. Additionally, stock-based compensation saw a substantial increase due to the issuance of 3,200,000 shares in January 2026, which contributed to the overall compensation expense.

As of June 30, 2026, Impact BioMedical reported total assets of $16,745,000, a decrease from $17,405,000 at the end of 2025. Current liabilities increased significantly to $2,045,000 from $1,162,000, primarily due to an increase in amounts due to related parties. The company’s stockholders' equity also declined to $10,766,000 from $12,311,000, reflecting the ongoing operational losses. The company continues to explore options for raising capital, including potential listings on the NYSE American and debt financing, as it seeks to stabilize its financial position and support future growth initiatives.

Looking ahead, Impact BioMedical remains focused on monetizing its intellectual properties and controlling operating costs to ensure its viability as a going concern. The company is actively evaluating additional technologies for development and commercialization, while also seeking strategic partnerships to enhance its product offerings in the biopharmaceutical and wellness sectors. The management's commitment to reducing costs and improving operational efficiency will be critical as the company navigates the challenges of the current market environment.